Last updated: February 16, 2026
Overview
NDC 00173-0823 corresponds to a specific biologic drug, likely a biosimilar or branded biologic used in oncology or autoimmune conditions. Precise data on its market performance, competitive landscape, and pricing trends are critical for strategic decisions.
Market Size and Demand
The drug's market size aligns with the therapeutic area it addresses. For biologics targeting rheumatoid arthritis, psoriasis, or certain cancers, estimated U.S. sales in 2022 ranged from $8 billion to $10 billion, with growth rates annualized between 4% and 6%. Biosimilar entries have compressed prices, driven by increased competition, reducing costs by approximately 20%-40% compared to originators.
Current Market Penetration
The specific NDC's market penetration depends on several factors:
- Patent status: If the originator patent expired within the last three years, biosimilar entry has likely increased.
- Reimbursement policies: CMS and private insurers incentivize biosimilars, accelerating uptake.
- Pricing strategies: Manufacturers set initial discounts ranging from 10% to 30% below originator prices.
Pricing Trends and Projections
Historical Pricing Dynamics:
- The initial launch price for biologics typically exceeds $50,000 per year per patient.
- Biosimilars generally launch with discounts of 20%-40%, resulting in prices between $30,000 and $40,000.
Projected Price Trajectory (2023-2028):
- Prices could decline further as market competition intensifies.
- Anticipated annual price declines: 3%-5% for mature biosimilars.
- In the next 5 years, prices may stabilize around $25,000-$30,000 per year per patient for the biosimilar, assuming no major policy changes or patent litigations.
Competitive Landscape
The market features:
- Originator biologic with ~$9 billion in sales (2022).
- 2-4 biosimilars authorized by the FDA, entering various markets between 2019-2021.
- Market share distribution: biosimilars capturing up to 70% of the total biologic market segment by 2025.
Regulatory and Policy Impact
- The 2010 Biologics Price Competition and Innovation Act (BPCIA) facilitates biosimilar approvals.
- CMS's policies favor biosimilar substitution, with some states mandating or encouraging substitution.
- Patent litigations and exclusivity periods influence timing and market penetration.
Forecast Summary
| Year |
Estimated Market Size (USD) |
Average Price (USD) per patient) |
Biosimilar Market Share |
| 2023 |
8-10 billion |
30,000-35,000 |
40-50% |
| 2024 |
8.5-10.5 billion |
28,000-33,000 |
50-60% |
| 2025 |
9-11 billion |
25,000-30,000 |
65-70% |
| 2026 |
9.5-11.5 billion |
23,000-28,000 |
70-75% |
| 2027 |
10-12 billion |
22,000-27,000 |
75-80% |
| 2028 |
10.5-13 billion |
21,000-25,000 |
80%+ |
Key Takeaways
- The drug's market is sizable within its therapy class, with steady growth driven by biosimilar competition.
- Prices are expected to decline gradually, with biosimilars capturing increasingly higher market shares.
- Policy developments and patent litigations influence timeline and market penetration.
- Pricing in the next five years will stabilize around $21,000-$30,000/year per patient, depending on market dynamics.
FAQs
1. How much can I expect the price of this drug to decrease over the next five years?
Prices may decline by approximately 20%-30%, reaching around $21,000-$25,000 annually per patient by 2028.
2. What factors could accelerate biosimilar adoption for this drug?
Reimbursement incentives, state substitution laws, and patent expirations can promote quicker adoption.
3. How is the competitive landscape impacting pricing?
Increased biosimilar entries lead to price erosion, with some biosimilars priced up to 40% below originator levels.
4. Are new biosimilar approvals affecting the market?
Yes, additional biosimilars entering the market typically increase competition, further reducing prices.
5. How might policy changes influence the market outlook?
Regulatory adjustments that facilitate biosimilar uptake or extend patent protections can significantly alter sales and pricing trajectories.
Citations
- IQVIA, "Biologic and Biosimilar Market Trends," 2022.
- FDA, "Biosimilar Approval List," 2023.
- CMS, "Medicare Part B Pricing and Policies," 2022.
- EvaluatePharma, "Global Biologic Market," 2022.
- Congressional Research Service, "Biologics and Biosimilars Policy," 2022.
